• Type: Recombinant vector vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: S protein (Bisht et al., 2004)
• S protein gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Vector: highly attenuated modified vaccinia virus Ankara (Bisht et al., 2004)
• Immunization Route: Intramuscular injection (i.m.)
• Description: Recombinant form of the highly attenuated modified vaccinia virus Ankara (MVA) containing the gene encoding full-length SARS-CoV S (Bisht et al., 2004)

• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: S protein (Woo et al., 2005)
• S protein gene of SARS-CoV gene engineering:
  • Type: Recombinant vector construction
  • Detailed Gene Information: Click Here.
• Immunization Route: Oral
• Description: oral live-attenuated auxotrophic S. typhimurium aroA strain SL7207 that contained tPA-optimize800 DNA vaccine (Woo et al., 2005)

• Type: DNA vaccine
• Status: Research
• Host Species for Licensed Use: None
• Host Species as Laboratory Animal Model: mouse
• Antigen: S protein (Woo et al., 2005)
• S protein gene of SARS-CoV gene engineering:
  • Type: DNA vaccine construction
  • Detailed Gene Information: Click Here.
• Immunization Route: Intramuscular injection (i.m.)
• Description: tPA-optimize800 DNA vaccine of SARS-CoV S protein (Woo et al., 2005)

Mouse Response

• Host Strain: Balb/c(Bisht et al., 2004)
• Vaccination Protocol: Mice were inoculated i.n. or i.m. with 10^7 pfu of MVA/S at time 0 and again at 4 weeks. (Bisht et al., 2004)
• Immune Response: Antibodies neturalized SARS-CoV in vitro after 2 doses (Bisht et al., 2004)
• Challenge Protocol: inoculated intranasally or intramuscularly with 7log pfu of MVA at 0 and 4 weeks then challenged with TCID50 of SARS-CoV (Bisht et al., 2004)
• Efficacy: little to no replication of SARS-CoV in the respiratory tracts after internasal inoculation(Bisht et al., 2004)

Mouse Response

• Host Strain: Balb/c (H-2d) (Woo et al., 2005)
• Vaccination Protocol: oral injection of 6e9 live attenuated Salmonella typhimurium that underwent transfection of tPA-S (Woo et al., 2005)
• Immune Response: neutralizing antibody titers of <1:20–1:160, lymphocyte proliteration, production of IFN-γ, production of IL-4 (48hrs) (Woo et al., 2005)

Mouse Response

• Host Strain: Balb/c (H-2d) (Woo et al., 2005)
• Vaccination Protocol: 100 μg of intramuscular administration of vaccine then 50 μg intraperitoneal injection of spike polypeptide at 28 and 42 days (Woo et al., 2005)
• Immune Response: neutralizing antibody titers of <1:20–1:160, lymphocyte proliteration, production of IFN-γ, production of IL-4 (48hrs) (Woo et al., 2005)